SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialisation of a diagnostic test for Alzheimer’s disease (AD), is pleased to announce the publication of “Morphometric imaging biomarker identifies Alzheimer’s disease even among mixed dementia patients” in Scientific Reports. Up until now, there have been no autopsy-validated tests shown to accurately identify AD…
Tecfidera lowers risk of first MS symptoms in RIS
Treatment with Tecfidera (dimethyl fumarate) significantly reduces the risk of experiencing the first multiple sclerosis (MS) symptoms in adults with radiologically isolated syndrome (RIS), according to data from a Phase 4 clinical trial which may lead to changes in practice. RIS is a condition in which patients have MS-like lesions on MRI scans, but lack typical symptoms of the disease. This…
EMD Serono highlights new data for Evobrutinib
First BTKi to demonstrate sustained clinical benefit for people with RMS through three and a half years of treatment Phase II clinical trial data of evobrutinib demonstrated low disease activity and stable EDSS, with NfL levels, a marker of neuronal injury, remaining low in people with RMS after three and a half years of therapy…
Laser Therapy for Epilepsy now available on the NHS
NHS England has accepted the recommendation of the Clinical Priorities Advisory Group to roll out LITT (laser interstitial thermal therapy) on the NHS. LITT is a laser treatment for epilepsy offering a less invasive alternative to conventional neurosurgery. It is a stereotactic procedure with the potential for seizure reduction results similar to those of open resection, with…
AssistiveTech in the UK
Ecosystem Overview and ATLAS Advocacy Launched in House of Lords AssistiveTech poised for rapid growth in the UK, tackling key socio-economic challenges. The official launch event and key findings of the new ‘AssistiveTech in the UK’ interactive report, developed by ATLAS (Assistive Technology, Longevity and Ageing Society) with the support of Aging Analytics Agency and…
Study reveals high neurodegenerative risk among former international rugby players
A study led by the University of Glasgow has revealed the first major insights into lifelong health outcomes in former international rugby union players. In findings published in the Journal of Neurology, Neurosurgery and Psychiatry, the researchers found that former international rugby players had an approximately two and a half times higher risk of neurodegenerative…
NICE publishes draft guidance on access to Duchenne treatment Translarna
NICE has published draft guidance stating that although Translarna (also known as ataluren) is clinically effective and an innovative treatment, there is doubt as to its cost effectiveness. NICE’s draft recommendation is that people currently receiving Translarna should continue to have access to it until they and their NHS clinician consider it appropriate to stop,…
Breakthrough in identifying common neural processes in Parkinson’s disease
New research could lead to treatments that halt the advance of Parkinson’s disease. Study from University of Haifa could have significant implications for how Parkinson’s disease is treated following a breakthrough in identifying common neural processes for the first time. A new study conducted by University of Haifa has identified processes that may help prevent…
AJOVY®▼ (fremanezumab) for treatment of migraine in patients with co-morbid depression
Two separate analyses1,2 presented at the Migraine Trust International Symposium (MTIS) demonstrate the effectiveness of AJOVY▼(fremanezumab) for the treatment of migraine in patients with migraine and co-morbid depression Depression and anxiety are common co-morbidities experienced by around half of all patients with migraine3,4 and are associated with more pain, disability and a reduced quality of…
